**Author Listing - Lead/ Submitting Author (we will be communicating with this individual): Name, Institution, City and State where the work was done. Co-authors will be added in a separate section.**
Francesco Cappelli; Tuscan Regional Amyloidosis Referral Centre, Careggi University Hospital, Florence, Italy; cappellif@aou-careggi.toscana.it

**Main Body of the Abstract**
Background: Transthyretin amyloid cardiomyopathy (ATTR-CM) causes a multidimensional patient burden. This study assessed ATTR-CM burden by severity of the patient’s heart failure.
Methods: Patients with ATTR-CM, recruited at international amyloidosis centers of excellence and naïve for disease-modifying therapy, completed surveys on various aspects of their disease burden.
Results: From July 2021 to August 2022, 208 patients in Europe, Australia, Canada, and Russia provided responses (median age of 81 years and 86% male). The population was relatively newly diagnosed (median 6 months; n=207), and 91% of the 155 patients with genetic testing had wild-type ATTR-CM. The incidence and severity of nearly all symptoms were higher in patients with New York Heart Association class III vs class I/II symptoms (Figure). Only 16% (7/43) of patients with class III symptoms reported that they could ‘walk normally’ vs 44% (68/154) of patients with class I/II symptoms. Overall, 53% and 51% of patients (both n=43) with class III symptoms reported an inability to participate in social and household activities, respectively, in the past 3 months (24% and 21% in patients with class I/II symptoms; n=152 and 151). Health status and quality of life were lower in patients with class III vs I/II symptoms (Figure).
Conclusions: ATTR-CM is a burden to patients, even when relatively newly diagnosed, and this burden is higher with more advanced disease. Patients frequently reported restricted mobility and difficulty undertaking social and household activities. Patients with NYHA class III symptoms reported poor to fair health, and lower than age-expected physicality.



Burden of transthyretin amyloid cardiomyopathy in treatment-naïve patients by heart failure severity: results from a large, non-interventional, real-world study PC30 (#4)

We invite you to attend the XIX International Symposium on Amyloidosis to be held in Rochester, MN.

This symposium is organized as a hybrid meeting (with the focus on in-person) held from Sunday, May 26 through Thursday, May 30, 2024.

Together with the ISA Board and members of Mayo Clinic, a very attractive scientific hybrid program is being planned. The program will cover a variety of types of systemic amyloidosis: ATTR (hereditary and wild-type), AL (light-chain), AA and less frequent forms. There will be key lectures, specific symposia including those company sponsored, oral presentations and poster sessions of accepted abstracts.

COURSE DESCRIPTION
This program will provide a comprehensive review of state-of-the-art education in systemic amyloidosis: basic science, pathophysiology, diagnosis, current and emerging treatments. Scientific presentations will include competitive oral and poster abstracts. The rapid evolution of scientific discovery and expanding treatment options has created tremendous interest in the field and this meeting will fill and important gap in educating scientists and clinicians.